-Regulatory submissions complete for exagamglogene autotemcel , formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia and severe sickle cell disease - -EU and U.K.. | May 8, 2023
Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be